Neurocrine Biosciences Inc - Asset Resilience Ratio
Neurocrine Biosciences Inc (NBIX) has an Asset Resilience Ratio of 16.57% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Neurocrine Biosciences Inc (NBIX) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Neurocrine Biosciences Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see NBIX total assets.
Liquid Assets Composition Over Time
This chart breaks down Neurocrine Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore NBIX long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $767.40 Million | 16.57% |
| Total Liquid Assets | $767.40 Million | 16.57% |
Asset Resilience Insights
- Good Liquidity Position: Neurocrine Biosciences Inc maintains a healthy 16.57% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Neurocrine Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Neurocrine Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for Neurocrine Biosciences Inc (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Neurocrine Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 16.57% | $767.40 Million | $4.63 Billion | -6.10pp |
| 2024-12-31 | 22.67% | $843.10 Million | $3.72 Billion | -1.33pp |
| 2023-12-31 | 24.01% | $780.50 Million | $3.25 Billion | -6.66pp |
| 2022-12-31 | 30.67% | $726.40 Million | $2.37 Billion | +12.79pp |
| 2021-12-31 | 17.88% | $370.50 Million | $2.07 Billion | -17.51pp |
| 2020-12-31 | 35.39% | $613.90 Million | $1.73 Billion | -7.36pp |
| 2019-12-31 | 42.74% | $558.25 Million | $1.31 Billion | -8.53pp |
| 2018-12-31 | 51.27% | $509.20 Million | $993.15 Million | +19.32pp |
| 2017-12-31 | 31.95% | $261.22 Million | $817.59 Million | -29.43pp |
| 2016-12-31 | 61.38% | $224.08 Million | $365.09 Million | -2.86pp |
| 2015-12-31 | 64.24% | $305.00 Million | $474.79 Million | -2.75pp |
| 2014-12-31 | 66.98% | $162.79 Million | $243.03 Million | +1.72pp |
| 2013-12-31 | 65.27% | $100.95 Million | $154.68 Million | +9.52pp |
| 2012-12-31 | 55.75% | $109.26 Million | $195.98 Million | -1.34pp |
| 2011-12-31 | 57.09% | $79.00 Million | $138.37 Million | +6.67pp |
| 2010-12-31 | 50.42% | $72.81 Million | $144.42 Million | +27.63pp |
| 2009-12-31 | 22.78% | $16.14 Million | $70.82 Million | +12.62pp |
| 2008-12-31 | 10.16% | $12.01 Million | $118.18 Million | -18.66pp |
| 2007-12-31 | 28.82% | $79.72 Million | $276.65 Million | +2.74pp |
| 2006-12-31 | 26.08% | $101.62 Million | $389.68 Million | -20.10pp |
| 2005-12-31 | 46.18% | $223.12 Million | $483.12 Million | -0.06pp |
| 2004-12-31 | 46.24% | $240.10 Million | $519.22 Million | -16.34pp |
| 2003-12-31 | 62.58% | $347.31 Million | $554.96 Million | -12.60pp |
| 2002-12-31 | 75.18% | $200.40 Million | $266.54 Million | +30.12pp |
| 2001-12-31 | 45.07% | $156.09 Million | $346.35 Million | -32.15pp |
| 2000-12-31 | 77.22% | $143.59 Million | $185.96 Million | +13.30pp |
| 1999-12-31 | 63.92% | $69.80 Million | $109.20 Million | -- |
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESS… Read more